KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $1.7 billion.

  • Halozyme Therapeutics' Non-Current Assets rose 7381.16% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 1376.8%. This contributed to the annual value of $1.7 billion for FY2025, which is 7381.16% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Non-Current Assets is $1.7 billion, which was up 7381.16% from $892.5 million recorded in Q3 2025.
  • Halozyme Therapeutics' Non-Current Assets' 5-year high stood at $1.7 billion during Q4 2025, with a 5-year trough of $24.9 million in Q1 2021.
  • For the 5-year period, Halozyme Therapeutics' Non-Current Assets averaged around $831.5 million, with its median value being $979.9 million (2024).
  • In the last 5 years, Halozyme Therapeutics' Non-Current Assets soared by 464649.41% in 2022 and then tumbled by 1631.96% in 2023.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Non-Current Assets stood at $178.1 million in 2021, then soared by 518.89% to $1.1 billion in 2022, then fell by 10.49% to $986.8 million in 2023, then decreased by 0.88% to $978.1 million in 2024, then skyrocketed by 73.81% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q4 2025, $892.5 million for Q3 2025, and $931.2 million during Q2 2025.